Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Oct 14:9:1017.
doi: 10.3389/fonc.2019.01017. eCollection 2019.

Efficacy and Safety of Hypofractionated Radiotherapy for the Treatment of Newly Diagnosed Glioblastoma Multiforme: A Systematic Review and Meta-Analysis

Guixiang Liao  1 , Zhihong Zhao  2 , Hongli Yang  1 , Xianming Li  1
Affiliations

Efficacy and Safety of Hypofractionated Radiotherapy for the Treatment of Newly Diagnosed Glioblastoma Multiforme: A Systematic Review and Meta-Analysis

Guixiang Liao et al. Front Oncol. .

Abstract

Background: Hypofractionated radiotherapy (HFR) is sometimes used in the treatment of glioblastoma multiforme (GBM). The efficacy and safety of HFR is still under investigation. The aim of this systematic review and meta-analysis was to provide a comprehensive summary of the efficacy and safety of HFR, and to compare the efficacy and safety of HFR and conventional fraction radiotherapy (CFR) for the treatment of patients with GBM, based on the results of randomized controlled trials (RCTs). Methods: A literature search was conducted to identify Phase II and III trials o comparing the efficacy and safety of HFR and CFR. Study selection, data extraction, and quality assessment, were conducted by two independent researchers. The analysis was performed using RevMan 5.3 and Stata 12.0. Results: Sixteen Phase II and III trials were included in the systematic review, and four RCTs were included in the meta-analysis. Participants treated with HRF and CRF had comparable overall survival (OS) (hazard ratio [HR]: 0.94, 95% confidence interval [CI]: 0.72-1.22, P = 0.64) and progression-free survival (PFS) (HR: 1.09, 95% CI: 0.60-1.95, P = 0.79), and similar rates of adverse events. However, in participants aged >70 years, those who received HFR had a higher OS than those who received CFR (HR: 0.59, 95% CI: 0.37-0.93, P = 0.02). Conclusions: HRF is efficacious and safe for the treatment of GBM. In individuals aged >70 years, treatment with HRF is superior to CFR in terms of OS. The role of HFR in the treatment of GBM in younger individuals and those with good prognostic factors requires further research.

Keywords: brain tumors; conventional fraction radiotherapy; glioblastoma multiforme; gliomas; hypofractionated radiotherapy; radiochemotherapy.

PubMed Disclaimer

Figures

Figure 1
Figure 1
The study selection process.
Figure 2
Figure 2
Risk of bias assessment.
Figure 3
Figure 3
Forest plots for overall survival between hoperfractionated radiotherapy (HFR) and conventional fraction radiotherapy (CFR).
Figure 4
Figure 4
Forest plots for progression-free survival between hoperfractionated radiotherapy (HFR) and conventional fraction radiotherapy (CFR).
Figure 5
Figure 5
A sensitivity analysis by omitting any single study for overall survival.
Figure 6
Figure 6
Publication was assessed by funnel plot of overall survival.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Ostrom QT, Gittleman H, Xu J, Kromer C, Wolinsky Y, Kruchko C, et al. . CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2009–2013. Neuro Oncol. (2016) 18:v1–75. 10.1093/neuonc/now207 - DOI - PMC - PubMed
    1. Chinot OL, Wick W, Mason W, Henriksson R, Saran F, Nishikawa R, et al. . Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma. N Engl J Med. (2014) 370:709–22. 10.1056/NEJMoa1308345 - DOI - PubMed
    1. Stupp R, Hegi ME, Mason WP, van den Bent MJ, Taphoorn MJ, Janzer RC, et al. . Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol. (2009) 10:459–66. 10.1016/S1470-2045(09)70025-7 - DOI - PubMed
    1. Shah JL, Li G, Shaffer JL, Azoulay MI, Gibbs IC, Nagpal S, et al. . Stereotactic radiosurgery and hypofractionated radiotherapy for glioblastoma. Neurosurgery. (2018) 82:24–34. 10.1093/neuros/nyx115 - DOI - PubMed
    1. Carlson JA, Reddy K, Gaspar LE, Ney D, Kavanagh BD, Damek D, et al. . Hypofractionated-intensity modulated radiotherapy (hypo-IMRT) and temozolomide (TMZ) with or without bevacizumab (BEV) for newly diagnosed glioblastoma multiforme (GBM): a comparison of two prospective phase II trials. J Neurooncol. (2015) 123:251–57. 10.1007/s11060-015-1791-4 - DOI - PubMed

Publication types